radium has been researched along with cabazitaxel in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 25 (83.33) | 24.3611 |
| 2020's | 5 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Sonpavde, G; Sternberg, CN | 1 |
| Beuzeboc, P; Goldwasser, F; Ropert, S; Zerbib, M | 1 |
| Lewis, B; Pal, SK; Sartor, O | 1 |
| Culine, S; Ouzaid, I; Pouessel, D; Ravery, V | 1 |
| Agarwal, N; Bellmunt, J; DiLorenzo, G; Sonpavde, G; Vogelzang, NJ; Zhang, TY | 1 |
| Kellokumpu-Lehtinen, P; Tammela, T | 1 |
| Joshua, AM; Leibowitz-Amit, R | 1 |
| Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
| D'Amico, AV | 1 |
| Bahl, A | 1 |
| Gurney, H; Parente, P; Parnis, F | 1 |
| Alcaraz, A; Caffo, O; da Silva, FC; Hammerer, P; Merseburger, AS; Roumeguère, T; Rozet, F | 1 |
| Attard, G; de Bono, JS; Lorente, D; Mateo, J; Perez-Lopez, R | 1 |
| Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Ackermann, CJ; Gillessen, S; Hager, S; Joerger, M; Omlin, A | 1 |
| Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S | 1 |
| Bolton, D; Corfield, J; Crozier, J; Joshua, AM; Lawrentschuk, N | 1 |
| Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A | 1 |
| Hinz, S | 1 |
| Heidenreich, A; Nilsson, S; Parker, C; Shore, N | 1 |
| Mulders, PFA; Niepel, D; Saad, F; Sternberg, CN; Tombal, BF | 1 |
| Buttigliero, C; Caffo, O; Cavaliere, C; D'aniello, C; Di Maio, M; Facchini, G; Kinspergher, S; Maines, F; Rizzo, M; Rossetti, S; Scagliotti, GV; Tucci, M; Veccia, A | 1 |
| Buonerba, C; Di Lorenzo, G; Fizazi, K; Pagliuca, M | 1 |
| Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W | 1 |
| Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D | 1 |
| Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK | 1 |
| Aben, KKH; Bergman, AM; Coenen, JLLM; de Wit, R; Gerritsen, WR; Kuppen, MCP; Mehra, N; Somford, DM; Uyl-de Groot, CA; van den Bergh, ACM; van den Eertwegh, AJM; van Moorselaar, RJA; van Oort, IM; Westgeest, HM | 1 |
| Alongi, F; Alongi, P; Baldari, S; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; Costa, RP; De Giorgi, U; De Vincentis, G; Donner, D; Facchini, G; Fanti, S; Frantellizzi, V; Galli, L; Lo Re, G; Masini, C; Monari, F; Morabito, A; Pignata, S; Pinto, C; Salgarello, M; Sbrana, A; Spada, M; Tucci, M; Zichi, C | 1 |
23 review(s) available for radium and cabazitaxel
| Article | Year |
|---|---|
Novel molecular targets for the therapy of castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstadienes; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Neoplasms; Cancer Vaccines; Carcinoma; Clinical Trials, Phase III as Topic; Clusterin; Dasatinib; Denosumab; Humans; Ipilimumab; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Pyridines; Pyrimidines; Quinolines; Quinolones; Radium; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Thiazoles; Tissue Extracts; Treatment Outcome; Vaccines, Synthetic | 2012 |
[Management of metastatic castration-resistant prostate cancer following docetaxel].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Treatment Failure | 2012 |
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Failure | 2012 |
[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Denosumab; Disease-Free Survival; France; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Tissue Extracts; Treatment Outcome | 2013 |
[Novel drugs provide better therapy for prostate cancer].
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids | 2013 |
The changing landscape in metastatic castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Quality of Life; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids | 2013 |
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2013 |
Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2014 |
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2015 |
Sequencing of agents in castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts; Treatment Outcome | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.
Topics: Androgen Receptor Antagonists; Benzamides; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Platinum Compounds; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2016 |
Understanding the role of new systemic agents in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2016 |
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
[Monitoring of treatment for metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Outcome and Process Assessment, Health Care; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
Current approaches to incorporation of radium-223 in clinical practice.
Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome | 2018 |
The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
Topics: Abiraterone Acetate; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Taxoids; Zoledronic Acid | 2018 |
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
Topics: Abiraterone Acetate; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2019 |
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Retrospective Studies; Taxoids; Thiohydantoins; Tissue Extracts | 2019 |
Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2020 |
Contemporary management of advanced prostate cancer: an evolving landscape.
Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational | 2021 |
7 other study(ies) available for radium and cabazitaxel
| Article | Year |
|---|---|
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.
Topics: Androstenes; Androstenols; Anilides; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Imidazoles; Ipilimumab; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Quinolines; Quinolones; Radioisotopes; Radium; Taxoids; Thionucleotides; Tissue Extracts | 2013 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts | 2015 |
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abdominal Neoplasms; Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2016 |
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids | 2020 |
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemoradiotherapy; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |